STAT+: Pharmalittle: We’re reading about CVS plans to split up, FDA inspections in India and China and more

CVS Health is planning a two-way breakup. One company would contain Aetna, its insurance business, and Caremark, its pharmacy-benefit manager. The other would operate CVS’s retail pharmacies. The plan matters because the businesses were deliberately combined in one of healthcare’s major consolidation deals.

The separation would undo the structure created when Aetna and CVS joined in a near-$70 billion merger. That deal brought insurance, pharmacy-benefit management, and retail pharmacy operations under one corporate umbrella. CVS has about 9,000 retail pharmacies, making the separation a large organizational change.

The breakup is expected in early 2028. The article does not provide details about new company names, leadership, ownership, or how stores and customers would be affected. It does establish that CVS is reversing a signature deal from roughly a decade ago and dividing the businesses by function.

Aetna is an insurance company within CVS Health. It helps provide health coverage and pays for eligible medical care. Caremark is a pharmacy-benefit manager, or PBM. It manages prescription-drug benefits, linking health plans, drug coverage, and pharmacy services. CVS’s retail pharmacies are the customer-facing stores where medicines are dispensed.

Their roles differ by place in the system. Aetna represents the insurance side. Caremark handles pharmacy-benefit administration. Retail pharmacies provide the physical location and dispensing operation for prescriptions. The article identifies Aetna as an insurance giant, Caremark as a pharmacy-benefit manager, and CVS as having about 9,000 retail pharmacies.

CVS currently houses these activities in one company, but plans to put Aetna and Caremark together in one company and retail pharmacies in another. The article does not describe their individual revenues, customers, or specific services. It does show that the split would separate financing and benefit management from pharmacy storefront operations.

The merger that brought Aetna and CVS together was worth nearly $70 billion. That figure indicates the transaction was not a small acquisition, but a major restructuring of healthcare businesses. It joined an insurance company with pharmacy-related operations under one corporate organization.

The retail side is also extensive. CVS has about 9,000 retail pharmacies, according to the article. These stores are the physical network distinguished from Aetna’s insurance operations and Caremark’s pharmacy-benefit management role. The planned split would therefore divide a very large store network from the other businesses.

The deal occurred about a decade before the planned early 2028 breakup. The article presents the merger as one of the signature transactions of an era of healthcare gigantism. It does not provide a current dollar value for CVS, Aetna, Caremark, or the retail pharmacy business, so the near-$70 billion merger value is the relevant scale measure.

The CVS-Aetna merger exemplified healthcare consolidation because it combined businesses spanning several parts of the industry. It brought an insurance giant, a pharmacy-benefit manager, and thousands of retail pharmacies under one company. The article describes this as part of an era of healthcare gigantism and a new breed of broadly integrated giants.

The planned separation would reverse that structure. Aetna and Caremark would remain together, while CVS’s retail pharmacies would form another company. In practical terms, insurance and pharmacy-benefit management would no longer share the same corporate home as the retail store network. That could make the businesses more distinct and easier to evaluate separately.

The article does not state whether prices, access, negotiating power, or competition would change. It only says CVS has decided to split in two and plans to complete the breakup in early 2028. Any effects beyond that organizational change remain unspecified in the provided text.

An unannounced FDA drug inspection is a regulatory examination of a drug facility carried out without advance notice. Inspectors can arrive without the facility receiving a planned appointment. The purpose is to assess conditions and practices as they normally operate, rather than only during a prepared visit.

A scheduled inspection gives a facility advance information about when inspectors will come. That notice can allow staff to organize records, arrange access, and prepare personnel. An unannounced inspection removes that preparation window. The article does not list the FDA’s inspection procedures or explain every difference between the two approaches, but it specifically tracks whether foreign inspections were unannounced.

The FDA increased such inspections in India and China during fiscal year 2026. Regulatory Focus attributed the increase to an effort to expand unannounced foreign inspections and achieve inspection parity between domestic and international facilities. The figures show a shift toward more surprise visits, not the total number of inspections.

The FDA reported much larger shares of unannounced inspections in both countries during fiscal year 2026. India’s share increased from 47% in fiscal year 2025 to 87% in fiscal year 2026. That is a rise of 40 percentage points, or nearly doubling the earlier share.

China’s share increased from 19% to 61% over the same fiscal years. The change was 42 percentage points. China therefore had a slightly larger percentage-point increase than India, even though its starting share was much lower. These figures describe proportions, not the total number of inspections conducted.

The article links the increases to the FDA’s effort to expand unannounced foreign inspections. The stated goal is inspection parity between domestic and international facilities. The data show stronger use of unannounced visits in both countries, but the article does not provide the underlying inspection counts or results.

The FDA inspects drug facilities in other countries to oversee facilities that may make medicines or ingredients for the U.S. market. Foreign production can affect the quality and reliability of drugs available to patients. The provided article focuses on inspection patterns and does not detail the FDA’s full legal authority or inspection checklist.

Inspection parity means seeking a comparable level of unannounced inspection at domestic and international facilities. If overseas sites receive less surprise oversight, differences in inspection practice could leave gaps in the regulator’s view of manufacturing conditions. More comparable oversight can make the system’s checks more consistent across locations.

The FDA increased the share of unannounced inspections in India from 47% to 87% and in China from 19% to 61% between fiscal years 2025 and 2026. The agency’s stated effort is to reach parity. The article does not report specific safety findings or prove that the increases changed drug quality.

Separating Aetna and Caremark from CVS’s retail pharmacies would divide insurance and pharmacy-benefit management from the store business. Patients could encounter changes in how those services are organized or connected, while insurers and pharmacy managers could operate under a different corporate structure. The article does not say whether patients would pay more, pay less, or experience access changes.

For pharmacy operations, the retail company would stand apart from the company containing Aetna and Caremark. That could change internal decision-making, contracts, or coordination, but those mechanisms are not described in the source. Competition could also be affected because the merger’s integrated structure would be reversed, yet the article provides no analysis of rivals or market shares.

The confirmed timing is early 2028. Until then, CVS remains the company housing the businesses described in the article. The source gives no announced consequences for patients, insurers, pharmacy workers, or competitors, so those outcomes cannot be stated as facts.